Gedeon Richter's US sales up by 36% in 2009
This article was originally published in Scrip
Executive Summary
Revenues from profit sharing agreements with Teva/Barr Pharmaceuticals and milestone payments from Forest Pharmaceuticals drove Gedeon Richter's US sales up by 36% to $177.4 million last year, with gynaecological products contributing more than 90% to the increase.